Navigation Links
Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes
Date:11/9/2008

Low-dose aspirin as primary prevention did not appear to significantly reduce the risk of a combined end point of coronary, cerebrovascular and peripheral vascular events in patients with type 2 diabetes, according to a new study in JAMA. However, aspirin did significantly reduce the combination of fatal coronary and fatal cerebrovascular events. The article is being released early online Sunday, November 9 to coincide with its scientific presentation at the American Heart Association meeting. The study will appear in the November 12 print issue of JAMA.

"Diabetes mellitus is a powerful risk factor for cardiovascular events," the authors write. "Individuals with diabetes have a two- to four-fold increased risk of developing cardiovascular events than those without diabetes." The authors note that the "American Diabetes Association recommends use of aspirin as a primary prevention strategy in patients with diabetes who are at increased cardiovascular risk," including those who are older than 40 years or who have additional risk factors, such as family history, hypertension or smoking.

In this study conducted by Hisao Ogawa, M.D., Ph.D., from the Graduate School of Medical Sciences, Kumamoto University, Japan and colleagues from the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators, the researchers examined whether low-dose aspirin would be beneficial for primary prevention of atherosclerotic (atherosclerosis, which involves narrowing or hardening of the arteries because of plaque build-up) events in patients with type 2 diabetes. From Dec. 2002 through April 2008, 2,539 patients with type 2 diabetes and no history of atherosclerotic disease from 163 institutions from throughout Japan were enrolled in the study. Patients were randomly assigned to the low-dose aspirin group receiving 81 or 100 mg per day (n = 1,262) or the nonaspirin (n = 1,277) group. The average age was 65 and 55 percent of the patients were men. The median (midpoint) follow-up period was 4.37 years. The main outcome measures were atherosclerotic events, including fatal or nonfatal ischemic heart disease, fatal or nonfatal stroke, and peripheral arterial disease.

"A total of 154 atherosclerotic events occurred: 68 in the aspirin group and 86 in the nonaspirin group," the researchers write. "In the 1,363 patients aged 65 years or older (719 in the aspirin group and 644 in the nonaspirin group), the incidence of atherosclerotic events was significantly lower in the aspirin group (45 events, 6.3 percent) than in the nonaspirin group (59 events, 9.2 percent)." In the 1,176 patients younger than 65 the difference among events in the two groups was not significant.

Aspirin was well tolerated: in comparing bleeding events, the researchers reported 13 hemorrhagic strokes, with no statistically significant difference between aspirin takers and non-takers (six such strokes in the aspirin group; seven in the non-aspirin group). There was a comparable number of the combined endpoint of serious hemorrhagic events (hemorrhagic strokes and major gastrointestinal bleeds).

"Myocardial infarction [heart attack] and ischemic stroke are leading causes of mortality and morbidity in patients with type 2 diabetes. Given the rapid increase in the number of patients with type 2 diabetes worldwide and especially in Asia, establishing effective means of primary prevention of coronary and cerebrovascular events is an important public health priority," the authors comment.

While this study did not find that low-dose aspirin significantly reduced the risk of atherosclerotic events in primary prevention therapy in patients with type 2 diabetes, the authors suggest more research is needed. "These findings should be interpreted in context with the low incidence of atherosclerotic disease in Japan and the current management practice for cardiovascular risk factors and suggest the need to conduct additional studies of aspirin for primary prevention of cardiovascular disease in diabetic patients."

(JAMA. 2008;300 [18]: 2134-2141. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: This study was supported by the Ministry of Health, Labour and Welfare of Japan. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: Aspirin For Primary Prevention Still an Open Question for Patients with Diabetes

"The use of aspirin for primary prevention of cardiovascular events in individuals with diabetes is widely recommended by existing guidelines, but the evidence supporting its efficacy is surprisingly scarce," writes Antonio Nicolucci, M.D., from Consorzio Mario Negri Sud, Italy, in an accompanying editorial.

"The lack of precision and the low statistical power in the JPAD trial are the consequence of the substantially lower than expected event rate in the trial population." Dr. Nicolucci writes that the study population had a very low baseline risk of cardiovascular events and questions whether the results can be generalized to other populations with substantially higher cardiovascular risks.

"The issue of aspirin therapy for patients with diabetes is an example of how, in the presence of a long-lasting uncertainty, scientific organizations or governmental bodies should provide the foundation for answering this question by promoting pragmatic, large-scale clinical trials. Considering all diabetic patients with no history of cardiovascular disease (except those with documented contraindications or perceived indications) as candidates for randomized clinical trials would represent a major contribution to the credibility of scientific methods in guiding practice."

(JAMA. 2008;300 [18]: 2180 2181. Available pre-embargo to the media at www.jamamedia.org.)


'/>"/>

Contact: Hisao Ogawa, M.D., Ph.D.
ogawah@kumamoto-u.ac.jp
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Bayer: Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained with Naproxen Sodium
2. Bayer Marketing Two Unapproved Aspirin Products: FDA
3. New CHARISMA Outcome Study Results Validate Aspirin Effect
4. Breakthrough Testing for Patients on Aspirin Therapy for Preventing Heart Attacks
5. Statement From Bayer(R) Aspirin Regarding the American Medical Associations New Aspirin Policy Resolution
6. Aspirin at Bedtime Lowers Blood Pressure
7. Anti-Clotting Drug as Good as Aspirin at Stopping Second Stroke
8. Daily Aspirin May Reduce Breast Cancer Risk
9. Daily aspirin may reduce risk of common type of breast cancer
10. Aspirin-like compounds increase insulin secretion in otherwise healthy obese people
11. Will botox be the aspirin of the 21st century?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Each year ... complementary medicine. Allison Outerbridge is this year’s Life University winner of ... at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last ...
(Date:5/26/2016)... ... 26, 2016 , ... W.S. Badger Co. Inc ., the maker of ... When Work Works Award for its use of effective workplace strategies to increase business ... project administered by the Families and Work Institute (FWI) and the Society for Human ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million ... million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world will ... Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration of ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found ... The 550 employees of Sun Health Senior Living (SHSL) may not share ... their doctor and prescription copays for the year, while holding the line on increasing ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... LONDON , May 24, 2016 ... erfüllt beide primären Endpunkte ... und Überlegenheit in ‚ausgezeichneter plus guter ... aufsteigenden Colons    ,      (Logo: ... B.V. gab heute neue positive Daten von der ...
(Date:5/24/2016)... Mass. , May 24, 2016  NxStage Medical, ... technology company focused on advancing renal care, today announced ... plans to participate in the following schedule of investor ... be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, June ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 /PRNewswire/ ... primer stent de doble terapia del mundo, introduce ... fístula arteriovenosa. OrbusNeich, una compañía global ... cambian las vidas, ha expandido su cartera incluyendo ... catéteres balón JADE™ y Scoreflex™ PTA son los ...
Breaking Medicine Technology: